Kamada (KMDA) Cash & Current Investments (2012 - 2026)
Kamada (KMDA) posted quarterly Cash & Current Investments of $73.1 million for Q1 2026, down 4.07% year-on-year from $76.2 million in Q1 2025, and down 3.33% on a QoQ basis from $75.7 million in Q4 2025.
Kamada (KMDA) Cash & Current Investments (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Cash & Current Investments for 15 consecutive years, with $73.1 million the latest figure, recorded in Q1 2026.
- Quarterly Cash & Current Investments fell 4.07% year-over-year to $73.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.1 million (down 4.07% YoY) and the FY2025 annual result came in at $75.7 million, down 3.59% from the prior year.
- Cash & Current Investments slipped to $73.1 million in Q1 2026 per KMDA's latest filing, from $75.7 million in the prior quarter.
- Over the last five years, Cash & Current Investments for KMDA reached as high as $31.3 billion in Q3 2022 and fell as low as $29933.0 in Q2 2022.
- A 5-year average of $1.9 billion and a median of $56.5 million in 2024 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2022 — Cash & Current Investments sank 99.97% — and 2023, when it jumped 72689.23%.
- Year by year, Cash & Current Investments stood at $34.3 million in 2022, then soared by 62.83% to $55.8 million in 2023, then jumped by 40.68% to $78.5 million in 2024, then slipped by 3.59% to $75.7 million in 2025, then fell by 3.33% to $73.1 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $73.1 million, $75.7 million, and $72.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 91.93 Bn | 90.07 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 36.31 Bn | 32.57 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 33.01 Bn | 31.07 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.65 Bn | 23.59 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 22.96 Bn | 20.81 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.50 Bn | 18.69 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 18.16 Bn | 16.85 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.84 Bn | 12.41 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Kamada | 403.42 Mn | 330.27 Mn | 19.12 Mn | 73.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.15 Mn |
| Dec 31, 2025 | 75.67 Mn |
| Sep 30, 2025 | 72.00 Mn |
| Jun 30, 2025 | 65.99 Mn |
| Mar 31, 2025 | 76.25 Mn |
| Dec 31, 2024 | 78.48 Mn |
| Sep 30, 2024 | 72.00 Mn |
| Jun 30, 2024 | 56.55 Mn |
| Mar 31, 2024 | 48.19 Mn |
| Dec 31, 2023 | 55.79 Mn |
| Sep 30, 2023 | 52.60 Mn |
| Jun 30, 2023 | 21.79 Mn |
| Mar 31, 2023 | 27.12 Mn |
| Dec 31, 2022 | 34.26 Mn |
| Sep 30, 2022 | 31.25 Bn |
| Jun 30, 2022 | 29,933.00 |
| Mar 31, 2022 | 21.97 Mn |
| Dec 31, 2021 | 145.29 Mn |
| Sep 30, 2021 | 99.84 Mn |
| Jun 30, 2021 | 104.55 Mn |